PT  - JOURNAL ARTICLE
AU  - Summers, Jaye
ED  - Macdonell, Richard
TI  - Teriflunomide Associated With Reductions in Severe MS Relapses
DP  - 2015 Jun 20
TA  - MD Conference Express
PG  - 17--18
VI  - 15
IP  - 9
4099  - http://mdc.sagepub.com/content/15/9/17.1.short
4100  - http://mdc.sagepub.com/content/15/9/17.1.full
AB  - The TEMSO and TOWER trials demonstrate that both doses of teriflunomide (7 mg and 14 mg) each significantly reduce the annualized relapse rates in patients with relapsing multiple sclerosis. Post hoc analyses of both trials indicate that only teriflunomide 14 mg significantly reduces the rate of all 5 markers of severe relapse in both studies.